Results 241 to 250 of about 4,014,515 (278)

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Comparison of two-stage methods for count data in Mendelian randomization: a simulation study. [PDF]

J Comp Eff Res
Appah M, Takei R, Srinivasasainagendra V, Vejandla SC, Reynolds RJ, Merriman TR, Tiwari HK.   +6 more
europepmc   +1 more source

Current Status and Influencing Factors of Insomnia Severity in Adolescents: A Cross-Sectional Study. [PDF]

Nat Sci Sleep
Huang HS, Zhang ZY, Xv R.
europepmc   +1 more source

Computational Modelling and Clinical Validation of an Alzheimer's-Related Network in Brain Cancer: The SKM034 Model. [PDF]

Curr Issues Mol Biol
Montalbo K, Stasik I, Smith CGS, Bakker EY.   +3 more
europepmc   +1 more source

Chatbot Outreach in Value-Based Preventive Care: Retrospective Analysis.

JMIR Med Inform
Chacko J, Jia Y, Stathakos K, Mazza K, Kim D, Diefenbach M, Carlo L.   +6 more
europepmc   +1 more source

Enhancing the Durability of Bituminous Concrete Using Plastic Waste on Soft Rock Aggregates. [PDF]

Polymers (Basel)
Laldintluanga H, Zorinkima, Ramhmachhuani R.   +2 more
europepmc   +1 more source

Early Prediction of Scar Outcomes: A Prospective Study on the Predictive Value of 3-Month Scar Assessments for 12-Month Results. [PDF]

Int Wound J
Li RA, Nguyen AT, Melnick BA, Ho KC, O'Connor MJ, Teven CM, Mustoe TA, Galiano RD.   +7 more
europepmc   +1 more source

Evolutionarily Optimal Risk Aversion. [PDF]

Risk Anal
Chmura, Nguyen, Biermann.
europepmc   +1 more source